These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22322837)

  • 1. Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma.
    Yan H; Wang R; Zhu K; Zhao W; Jiang S; Feng R; Xu X; Meng X; Sun H; Zhang H; Mu D; Xu Z
    Tumori; 2011; 97(6):717-23. PubMed ID: 22322837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
    Zeng ZF; Ding PR; Pan ZZ; Lin JZ; Li LR; Lu ZH; Wu XJ; Kong LH; Zhou ZG; Wan DS
    Ai Zheng; 2009 Sep; 28(9):923-7. PubMed ID: 19728908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy.
    Yeo SG; Kim DY; Chang HJ; Park JW; Oh JH; Kim BC; Baek JY; Kim SY; Kim TH
    Tumori; 2013; 99(1):93-9. PubMed ID: 23549007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels.
    Huang D; Lin Q; Song J; Xu B
    Dig Surg; 2021; 38(1):24-29. PubMed ID: 33171467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
    Das P; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Wolff RA; Eng C; Krishnan S; Janjan NA; Crane CH
    Cancer; 2007 May; 109(9):1750-5. PubMed ID: 17387743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant conformal chemoradiation with induction chemotherapy for rectal adenocarcinoma. A prospective observational study.
    Fekete Z; Muntean AS; Hica Ş; Rancea A; Resiga L; Csutak C; Todor N; Nagy VM
    J Gastrointestin Liver Dis; 2014 Jun; 23(2):171-8. PubMed ID: 24949609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
    Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Morikawa T; Fukayama M; Watanabe T
    Dis Colon Rectum; 2017 Apr; 60(4):368-375. PubMed ID: 28267003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma].
    Lin JZ; Pan ZZ; Zeng ZF; Ding PR; Wan DS
    Ai Zheng; 2009 Sep; 28(9):919-22. PubMed ID: 19728907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
    Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
    Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
    Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of the circumferential extent of tumors and clinical lymph node status as prognostic factors after preoperative chemoradiotherapy and surgery in patients with rectal cancer.
    Yoon WS; Park W; Choi DH; Ahn YC; Chun HK; Lee WY; Yun SH; Kang WK; Lim HY; Park YS
    Tumori; 2010; 96(4):568-76. PubMed ID: 20968136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
    Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
    Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
    Marks EI; Brennan M; El-Deiry WS
    Cancer Biol Ther; 2015; 16(8):1136-9. PubMed ID: 26047368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
    Wang CC; Liang JT; Tsai CL; Chen YH; Lin YL; Shun CT; Cheng JC
    World J Surg Oncol; 2014 Nov; 12():329. PubMed ID: 25373828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.
    Yang KL; Yang SH; Liang WY; Kuo YJ; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC; Chu LS; Wang LW
    Radiat Oncol; 2013 Mar; 8():43. PubMed ID: 23452434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.